Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study

Figures & data

Figure 1. —Study flow of patient numbers.

Table 1. —Patient characteristics.

Age (years) (n = 136)	Mean (SD)	41.26 (14.522)
	Median (range)	42.82 (12.1–83.6)
Age distribution (n = 136)	12–18 years	9 (6.6%)
	18–45 years	69 (50.7%)
	>45 years	58 (42.6%)
Sex (n = 136)	Male	43 (31.6%)
	Female	93 (68.4%)
Smoking history (n = 136)	Current smoker	3 (2.2%)
	Ex-smoker	24 (17.6%)
	Never smoked	89 (65.4%)
	Not recorded	20 (14.7%)
Pack-years (n = 16)	Mean (SD)	10.76 (14.378)
	Median (range)	7.50 (0.2-60.0)
Last recorded weight pre-OMB (kg) (n = 132)	Mean (SD)	81.16 (20.632)
	Median (range)	81.25 (40.3–133.0)
Age at asthma diagnosis (years) (n = 120)	Mean (SD)	14.59 (15.657)
	Median (range)	8.00 (0–72.0)
Duration of severe persistent allergic asthma (years) (n = 120)	Mean (SD)	26.44 (14.266)
	Median (range)	25.80 (2.9–57.5)
Allergies pre-dating OMB initiation (n = 136)	Allergen	No. patients (%)
	Animal fur (inc. cats, dogs)	79 (58.1%)
	Pollen	64 (47.1%)
	House dust (mite)	62 (45.6%)
	Plant material	32 (23.5%)
	Fruit (inc. strawberries)	14 (10.3%)
	Antibiotic	13 (9.6%)
	Other drug	11 (8.1%)
	Nuts (inc. peanut)	11 (8.1%)
	Moulds	9 (6.6%)
	Milk	6 (4.4%)
	Fish/shellfish	6 (4.4%)
	Egg	5 (3.7%)
	Feathers	2 (1.5%)
	Other	36 (26.5%)
	None	8 (5.9%)

Figure 2. —Daily dose of OCS (mg) in the 1 year pre- and post-OMB.

Table 2. —Lung function tests.

N = 136	Baseline	Post-Omalizumab	Difference	% Difference	P- value
Mean FEV1(% predicted)
16 weeks (n = 111)	62.94	70.98	8.05	12.8%	<.001
Most recent (approx. 12 months) (n = 32)	69.90	78.60	8.70	12.4%	.0020
Mean FEV1(L)
16 weeks (n = 88)	1.99	2.10	0.10	5.5%	.2157
Most recent (approx. 12 months) (n = 70)	1.99	2.22	0.24	12.1%	<.001
Mean PEF(L/min)
16 weeks (n = 91)	296.89	348.51	51.62	17.4%	<.001
Most recent (approx. 12 months) (n = 58)	299.24	326.79	27.55	9.2%	.0040

Figure 3. —Median ACT score. An ACT score below 19/25 indicates poorly controlled asthma.

Figure 4. —Median AQLQ score. The AQLQ works on a maximum possible score 7, where lower scores indicate a poorer quality of life.

Table 3. —Hospital resource use (excluding visits for OMALIZUMAB administration).

	Mean (SD)	Mean (SD)
Resource	pre-OMALIZUMAB	post-OMALIZUMAB	Difference	Paired t-test
A&E visits	1.52 (2.194)	0.46 (1.419)	−1.07 (2.383)	p < .001
Inpatient hospitalizations	1.30 (1.731)	0.51 (1.102)	−0.79 (1.830)	p < .001
Bed days (all subjects)	9.10 (14.438)	2.97 (6.343)	−6.13 (14.243)	p < .001
Inpatient hospitalizations (hospitalized subset^a, n = 81)	2.19 (1.761)	0.65 (1.247)	−1.53 (1.963)	p < .001
Bed days (hospitalized subset, n = 81)	14.86 (16.341)	3.83 (6.939)	−11.04 (16.176)	p < .001
Respiratory outpatient visits	6.00 (3.432)	5.71 (4.360)	−0.29 (4.968)	p = .49
Telephone consultations	0.23 (0.877)	0.11 (0.416)	−0.12 (0.656)	p= .0384
Nurse consultations	1.24 (2.209)	1.69 (3.954)	0.46 (3.559)	p = .1375
Doctor consultations	4.54 (3.277)	3.82 (3.250)	−0.71 (3.434)	p = .0168
MDT consultations	0.06 (0.266)	0.00 (0.000)	−0.06 (0.266)	p = .0109
Pharmacist consultations	0.05 (0.372)	0.06 (0.360)	0.01 (0.333)	p = .7973

Note: ^aPatients hospitalized in the 12 months pre-OMALIZUMAB initiation.